Bradley E. Aouizerat

Faculty

Bradley E. Aouizerat headshot

Bradley E. Aouizerat

PhD

Professor, College of Dentistry

Bradley E. Aouizerat's additional information

BS, Microbiology/ Molecular Genetics - University of California at Los Angeles
PhD, Microbiology/ Molecular Genetics/lmmunology - University of California at Los Angeles
MAS, Master of Advance Science Research in Clinical - University of California at San Francisco

Oral-systemic health

American Heart Association
American Liver Foundation
American Pain Society
American Society for Human Genetics
International Association for the Study of Pain

Faculty Honors Awards

Excellence in Research Mentoring Faculty Teaching Award (2013)
Excellence in Research Mentoring Faculty Teaching Award (Nominee) (2012)
Excellence in Research Mentoring Faculty Teaching Award (Nominee) (2011)
Most Dedicated Mentor Award, PMCTR Fellowship Program (2009)
Early Career Investigator Award, Bayer Healthcare International (2006)
Multidisciplinary Clinical Research Scholar, Roadmap K12 (2006)
Early Career Faculty Award, Hellman Family (2005)
Faculty Mentorship Award Nominee (2005)
Young Investigator Award, National Hemophilia Foundation (2005)
National Liver Scholar Award, American Liver Foundation (2004)
Irvine H. Page Young Investigator Award (Finalist), American Heart Association (2004)
Faculty Mentorship Award Nominee (2004)
Sam and Rose Gilbert Fellowship, UCLA (1998)
Warsaw Fellowship (1998)

Publications

Preoperative breast pain predicts persistent breast pain and disability after breast cancer surgery

Langford, D. J., Schmidt, B., Levine, J. D., Abrams, G., Elboim, C., Esserman, L., Hamolsky, D., Mastick, J., Paul, S. M., Cooper, B., Kober, K., Dodd, M., Dunn, L., Aouizerat, B., & Miaskowski, C. (2015). Journal of Pain and Symptom Management, 49(6), 981-994. 10.1016/j.jpainsymman.2014.11.292
Abstract
Abstract
Context Approximately 30% of the women report pain in the affected breast before breast cancer surgery. Objectives The purpose of this secondary analysis of our prospective study was to determine how women who experienced both preoperative and persistent postsurgical breast pain (n = 107) differed from women who did not report preoperative breast pain and did (n = 158) or did not (n = 122) experience persistent postsurgical breast pain. Methods Differences in demographic and clinical characteristics were evaluated. Linear mixed effects (LME) modeling was used to evaluate for group differences in symptom severity, function, sensation, and quality of life (QOL) over time. Results Between-group differences in demographic and clinical characteristics as well as trajectories of shoulder function and QOL were identified. Women with both preoperative and persistent postsurgical breast pain were younger; were more likely to report swelling, strange sensations, hardness, and numbness in the affected breast before surgery; and were more likely to have reconstruction at the time of surgery. Women with both preoperative and persistent postsurgical breast pain had more biopsies in the prior year, more lymph nodes removed, and reported more severe acute postsurgical pain than women without preoperative breast pain. The LME modeling revealed significant group effects for most outcomes evaluated. Over the six months of the study, women with both preoperative and persistent postsurgical pain had persistently poorer shoulder flexion and physical well-being than women without preoperative breast pain. Conclusion Investigations of the etiology and molecular mechanisms of preoperative breast pain, as well as interventions for this high-risk group, are needed.

Risk of breast cancer with CXCR4-using HIV defined by V3 loop sequencing

Goedert, J. J., Swenson, L. C., Napolitano, L. A., Haddad, M., Anastos, K., Minkoff, H., Young, M., Levine, A., Adeyemi, O., Seaberg, E. C., Aouizerat, B., Rabkin, C. S., Richard Harrigan, P., & Hessol, N. A. (2015). Journal of Acquired Immune Deficiency Syndromes, 68(1), 30-35. 10.1097/QAI.0000000000000400
Abstract
Abstract
Objective: Evaluate the risk of female breast cancer associated with HIV-CXCR4 (X4) tropism as determined by various genotypic measures. Methods: A breast cancer case-control study, with pairwise comparisons of tropism determination methods, was conducted. From the Women's Interagency HIV Study repository, one stored plasma specimen was selected from 25 HIV-infected cases near the breast cancer diagnosis date and 75 HIV-infected control women matched for age and calendar date. HIV-gp120 V3 sequences were derived by Sanger population sequencing (PS) and 454-pyro deep sequencing (DS). Sequencingbased HIV-X4 tropism was defined using the geno2pheno algorithm, with both high-stringency DS [false-positive rate (3.5) and 2% X4 cutoff], and lower stringency DS (false-positive rate, 5.75 and 15% X4 cutoff). Concordance of tropism results by PS, DS, and previously performed phenotyping was assessed with kappa (k) statistics. Case-control comparisons used exact P values and conditional logistic regression. Results: In 74 women (19 cases, 55 controls) with complete results, prevalence of HIV-X4 by PS was 5% in cases vs 29% in controls (P = 0.06; odds ratio, 0.14; confidence interval: 0.003 to 1.03). Smaller case-control prevalence differences were found with highstringency DS (21% vs 36%, P = 0.32), lower stringency DS (16% vs 35%, P = 0.18), and phenotyping (11% vs 31%, P = 0.10). HIVX4 tropism concordance was best between PS and lower stringency DS (93%, k = 0.83). Other pairwise concordances were 82%-92% (k = 0.56-0.81). Concordance was similar among cases and controls. Conclusions: HIV-X4 defined by population sequencing (PS) had good agreement with lower stringency DS and was significantly associated with lower odds of breast cancer..

Trajectories of evening fatigue in oncology outpatients receiving chemotherapy

Wright, F., D’Eramo Melkus, G., Hammer, M., Schmidt, B. L., Knobf, M. T., Paul, S. M., Cartwright, F., Mastick, J., Cooper, B. A., Chen, L. M., Melisko, M., Levine, J. D., Kober, K., Aouizerat, B. E., & Miaskowski, C. (2015). Journal of Pain and Symptom Management, 50(2), 163-175. 10.1016/j.jpainsymman.2015.02.015
Abstract
Abstract
Context Fatigue is a distressing persistent sense of physical tiredness that is not proportional to a person's recent activity. Fatigue impacts patients' treatment decisions and can limit their self-care activities. Although significant interindividual variability in fatigue severity has been noted, little is known about predictors of interindividual variability in initial levels and trajectories of evening fatigue severity in oncology patients receiving chemotherapy. Objectives To determine whether demographic, clinical, and symptom characteristics were associated with initial levels and the trajectories of evening fatigue. Methods A sample of outpatients with breast, gastrointestinal, gynecological, and lung cancer (N = 586) completed demographic and symptom questionnaires a total of six times over two cycles of chemotherapy. Fatigue severity was evaluated using the Lee Fatigue Scale. Hierarchical linear modeling was used to answer the study objectives. Results A large amount of interindividual variability was found in the evening fatigue trajectories. A piecewise model fit the data best. Patients who were white, diagnosed with breast, gynecological, or lung cancer, and who had more years of education, childcare responsibilities, lower functional status, and higher levels of sleep disturbance and depression reported higher levels of evening fatigue at enrollment. Conclusion This study identified both nonmodifiable (e.g., ethnicity) and modifiable (e.g., childcare responsibilities, depressive symptoms, sleep disturbance) risk factors for more severe evening fatigue. Using this information, clinicians can identify patients at higher risk for more severe evening fatigue, provide individualized patient education, and tailor interventions to address the modifiable risk factors.

Variations in potassium channel genes are associated with distinct trajectories of persistent breast pain after breast cancer surgery

Langford, D. J., Paul, S. M., West, C. M., Dunn, L. B., Levine, J. D., Kober, K. M., Dodd, M. J., Miaskowski, C., & Aouizerat, B. E. (2015). Pain, 156(3), 371-380. 10.1097/01.j.pain.0000460319.87643.11
Abstract
Abstract
Persistent pain after breast cancer surgery is a common clinical problem. Given the role of potassium channels in modulating neuronal excitability, coupled with recently published genetic associations with preoperative breast pain, we hypothesized that variations in potassium channel genes will be associated with persistent postsurgical breast pain. In this study, associations between 10 potassium channel genes and persistent breast pain were evaluated. Using growth mixture modeling (GMM), 4 distinct latent classes of patients, who were assessed before and monthly for 6 months after breast cancer surgery, were identified previously (ie, No Pain, Mild Pain, Moderate Pain, Severe Pain). Genotyping was done using a custom array. Using logistic regression analyses, significant differences in a number of genotype or haplotype frequencies were found between: Mild Pain vs No Pain and Severe Pain vs No Pain classes. Seven single-nucleotide polymorphisms (SNPs) across 5 genes (ie, potassium voltage-gated channel, subfamily A, member 1 [KCNA1], potassium voltage-gated channel, subfamily D, member 2 [KCND2], potassium inwardly rectifying channel, subfamily J, members 3 and 6 (KCNJ3 and KCNJ6), potassium channel, subfamily K, member 9 [KCNK9]) were associated with membership in the Mild Pain class. In addition, 3 SNPs and 1 haplotype across 4 genes (ie, KCND2, KCNJ3, KCNJ6, KCNK9) were associated with membership in the Severe Pain class. These findings suggest that variations in potassium channel genes are associated with both mild and severe persistent breast pain after breast cancer surgery. Although findings from this study warrant replication, they provide intriguing preliminary information on potential therapeutic targets.

Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer

Merriman, J. D., Aouizerat, B. E., Cataldo, J. K., Dunn, L., Cooper, B. A., West, C., Paul, S. M., Baggott, C. R., Dhruva, A., Kober, K., Langford, D. J., Leutwyler, H., Ritchie, C. S., Abrams, G., Dodd, M., Elboim, C., Hamolsky, D., Melisko, M., & Miaskowski, C. (2014). Cytokine, 65(2), 192-201. 10.1016/j.cyto.2013.11.003
Abstract
Abstract
Subgroups of patients with breast cancer may be at greater risk for cytokine-induced changes in cognitive function after diagnosis and during treatment. The purposes of this study were to identify subgroups of patients with distinct trajectories of attentional function and evaluate for phenotypic and genotypic (i.e., cytokine gene polymorphisms) predictors of subgroup membership. Self-reported attentional function was evaluated in 397 patients with breast cancer using the Attentional Function Index before surgery and for six months after surgery (i.e., seven time points). Using growth mixture modeling, three attentional function latent classes were identified: High (41.6%), Moderate (25.4%), and Low-moderate (33.0%). Patients in the Low-moderate class were significantly younger than those in the High class, with more comorbidities and lower functional status than the other two classes. No differences were found among the classes in years of education, race/ethnicity, or other clinical characteristics. DNA was recovered from 302 patients' samples. Eighty-two single nucleotide polymorphisms among 15 candidate genes were included in the genetic association analyses. After controlling for age, comorbidities, functional status, and population stratification due to race/ethnicity, IL1R1 rs949963 remained a significant genotypic predictor of class membership in the multivariable model. Carrying the rare "A" allele (i.e., GA. +. AA) was associated with a twofold increase in the odds of belonging to a lower attentional function class (OR: 1.98; 95% CI: 1.18, 3.30; p=.009). Findings provide evidence of subgroups of women with breast cancer who report distinct trajectories of attentional function and of a genetic association between subgroup membership and an IL1R1 promoter polymorphism.

Association of CASQ2 polymorphisms with sudden cardiac arrest and heart failure in patients with coronary artery disease

Refaat, M. M., Aouizerat, B. E., Pullinger, C. R., Malloy, M., Kane, J., & Tseng, Z. H. (2014). Heart Rhythm, 11(4), 646-652. 10.1016/j.hrthm.2014.01.015
Abstract
Abstract
Background: Abnormal calcium handling plays a crucial role in arrhythmias, sudden cardiac arrest (SCA), and congestive heart failure (CHF). Calsequestrin 2 (CASQ2) mutations affect calcium release and initiate malignant ventricular arrhythmias (VAs) and SCA syndromes. Common single nucleotide polymorphisms (SNPs) in CASQ2 may be associated with SCA in patients with coronary artery disease (CAD). Objective: The purpose of this study was to examine the association of common CASQ2 SNPs with the risk of SCA in patients with CAD. Methods: CASQ2 SNPs (n = 14) were genotyped and analyzed in a case control study comparing 114 patients with CAD and SCA due to VA to 311 CAD controls without VA or SCA. Results: Multivariate logistic regression adjusting for age and CHF status identified an association between rs7521023 with SCA (odds ratio [OR] 2.72, 95% confidence interval [CI] 1.44-5.13, P = .002). The substantial impact of CHF on SCA in the model (OR 26.6, 95% CI 13.40-52.70, P <.001) led us to further examine the relationship between CHF, SCA, and CASQ2 SNPs. We identified 2 CASQ2 variants (rs7521023: OR 0.4, 95% CI 0.25-0.76, P = .003; rs6684209: OR 19.8, 95% CI 3.63-108.2, P <.001) associated with CHF after adjusting for SCA, age, gender, and hypertension. Conclusion: We observed association between a CASQ2 polymorphism and SCA due to VA in patients with CAD adjusting for CHF and independent associations between CASQ2 SNPs and CHF adjusting for SCA. Further investigation in independent cohorts is needed to confirm these findings.

Associations between cytokine gene variations and self-reported sleep disturbance in women following breast cancer surgery

Alfaro, E., Dhruva, A., Langford, D. J., Koetters, T., Merriman, J. D., West, C., Dunn, L. B., Paul, S. M., Cooper, B., Cataldo, J., Hamolsky, D., Elboim, C., Kober, K., Aouizerat, B. E., & Miaskowski, C. (2014). European Journal of Oncology Nursing, 18(1), 85-93. 10.1016/j.ejon.2013.08.004
Abstract
Abstract
Purpose of the research: To attempt to replicate the associations found in our previous study of patients and family caregivers between interleukin 6 (IL6) and nuclear factor kappa beta 2 (NFKB2) and sleep disturbance and to identify additional genetic associations in a larger sample of patients with breast cancer. Methods and sample: Patients with breast cancer (n=398) were recruited prior to surgery and followed for six months. Patients completed a self-report measure of sleep disturbance and provided a blood sample for genomic analyses. Growth mixture modeling was used to identify distinct latent classes of patients with higher and lower levels of sleep disturbance. Key results: Patients who were younger and who had higher comorbidity and lower functional status were more likely to be in the high sustained sleep disturbance class. Variations in three cytokine genes (i.e., IL1 receptor 2 (IL1R2), IL13, NFKB2) predicted latent class membership. Conclusions: Polymorphisms in cytokine genes may partially explain inter-individual variability in sleep disturbance. Determination of high risk phenotypes and associated molecular markers may allow for earlier identification of patients at higher risk for developing sleep disturbance and lead to the development of more targeted clinical interventions.

Associations between cytokine gene variations and severe persistent breast pain in women following breast cancer surgery

Stephens, K., Cooper, B. A., West, C., Paul, S. M., Baggott, C. R., Merriman, J. D., Dhruva, A., Kober, K. M., Langford, D. J., Leutwyler, H., Luce, J. A., Schmidt, B. L., Abrams, G. M., Elboim, C., Hamolsky, D., Levine, J. D., Miaskowski, C., & Aouizerat, B. E. (2014). Journal of Pain, 15(2), 169-180. 10.1016/j.jpain.2013.09.015
Abstract
Abstract
Persistent pain following breast cancer surgery is a significant clinical problem. Although immune mechanisms may play a role in the development and maintenance of persistent pain, few studies have evaluated for associations between persistent breast pain following breast cancer surgery and variations in cytokine genes. In this study, associations between previously identified extreme persistent breast pain phenotypes (ie, no pain vs severe pain) and single nucleotide polymorphisms (SNPs) spanning 15 cytokine genes were evaluated. In unadjusted analyses, the frequency of 13 SNPs and 3 haplotypes in 7 genes differed significantly between the no pain and severe pain classes. After adjustment for preoperative breast pain and the severity of average postoperative pain, 1 SNP (ie, interleukin [IL] 1 receptor 2 rs11674595) and 1 haplotype (ie, IL10 haplotype A8) were associated with pain group membership. These findings suggest a role for cytokine gene polymorphisms in the development of persistent breast pain following breast cancer surgery. Perspective This study evaluated for associations between cytokine gene variations and the severity of persistent breast pain in women following breast cancer surgery. Variations in 2 cytokine genes were associated with severe breast pain. The results suggest that cytokines play a role in the development of persistent postsurgical pain.

Contribution of sleep disturbance to cancer fatigue

Miaskowski, C., & Aouizerat, B. E. (2014). In Impact of Sleep and Sleep Disturbances on Obesity and Cancer (1–, pp. 169-192). Springer New York. 10.1007/978-1-4614-9527-7_9
Abstract
Abstract
Oncology patients are at high risk for developing sleep disturbance and fatigue due a number of physiological and psychological factors associated with cancer, its treatment, and the burden of living with a chronic condition. Progress in our understanding of sleep disturbance and fatigue in oncology patients has been stymied by varying definitions for each symptom, as well as different instruments to measure each symptom. In addition, the co-occurrence of these and other common symptoms suggests that analytic methodologies that are currently available should be considered to model the relationships between these and among other common symptoms. The purpose of the chapter is to describe the prevalence, risk factors, measurement considerations, proposed mechanisms for and novel approaches to the study of these two common symptoms in oncology patients. Interventions to improve sleep and reduce fatigue are also described.

Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery

Leung, G., Baggott, C., West, C., Elboim, C., Paul, S. M., Cooper, B. A., Abrams, G., Dhruva, A., Schmidt, B. L., Kober, K., Merriman, J. D., Leutwyler, H., Neuhaus, J., Langford, D., Smoot, B. J., Aouizerat, B. E., & Miaskowski, C. (2014). Lymphatic Research and Biology, 12(1), 10-22. 10.1089/lrb.2013.0024
Abstract
Abstract
Background: Lymphedema (LE) is a frequent complication following breast cancer treatment. While progress is being made in the identification of phenotypic risk factors for the development of LE, little information is available on the molecular characterization of LE. The purpose of this study was to determine if variations in pro-and anti-inflammatory cytokine genes were associated with LE following breast cancer treatment. Methods and Results: Breast cancer patients completed a number of self-report questionnaires. LE was evaluated using bioimpedance spectroscopy. Genotyping was done using a custom genotyping array. No differences were found between patients with (n=155) and without LE (n=387) for the majority of the demographic and clinical characteristics. Patients with LE had a significantly higher body mass index, more advanced disease, and a higher number of lymph nodes removed. Genetic associations were identified for three genes (i.e., interleukin (IL4) 4 (rs2227284), IL 10 (rs1518111), and nuclear kappa factor beta 2 (NFKB2 (rs1056890)) associated with inflammatory responses. Conclusions: These genetic associations suggest a role for a number of pro-and anti-inflammatory genes in the development of LE following breast cancer treatment.